Category Archives: AP26113 – brigatinib from Ariad

Ariad files FDA application and gets acquired

As of August 30, 2016 Arriad had files its new drug application with the FDA for brigatinib. As of Oct 31, 2016 the FDA granted ARIAD’s request for Priority Review and has set an action date of April 29, 2017. As of January … Continue reading

Posted in AP26113 - brigatinib from Ariad, Lung cancer, Regulatory applications & approvals | Leave a comment

Update on Novartis and Ariad trials

As of Dec. 6, 2016 Novartis and Ariad announced research updates In Phase III study by Novartis on Zykadia® (ceritinib) as a first-line treatment, they found a 45% reduction in the risk of disease progression. The study found a median progression free survival … Continue reading

Posted in Anaplastic Large-Cell Lymphomas, AP26113 - brigatinib from Ariad, Brain metastases, ceritinib - Zykadia from Novartis, Lung cancer, Potential Treatments, Research | Leave a comment

Abstract 9007 on Brigatinib update

The initial write up of the abstract 9007 was posted on May 19. This update covers about 3 more months of data and brain mets. Arm A (90 mg) median Progression Free Survival (PFS) increased from 8.8 months to 9.2 … Continue reading

Posted in AP26113 - brigatinib from Ariad, Brain metastases, Lung cancer, Potential Treatments, Research | Leave a comment

Outcomes for ALK+ patients

Abstract e20550 is from Spain and involves 49 patients. Patients took 6 different ALK inhibitors. The abstract concluded “ALK+ patients who received targeted agents have prolonged survival despite brain metastases…. ALK inhibitors improve intracranial response rate and survival.”

Posted in 3922 - lorlatinib by Pfizer, alectinib - Alecensa from Chugai - Roche - GenenTech, AP26113 - brigatinib from Ariad, Brain metastases, ceritinib - Zykadia from Novartis, crizotinib - Xalkori from Pfizer, Lung cancer, Potential Treatments, Research | Leave a comment

Britatinib abstract

Abstract 9007 covers the Phase 2 trial (ALTA) comparing two dosing schemes. There were 222 patients who had progressed on Crizotinib. Results where as of 12-7-15. Arm A received 90 mg straight through.  Arm Breceived 90 mg for the first … Continue reading

Posted in AP26113 - brigatinib from Ariad, Lung cancer, Potential Treatments, Research, Side Effects | Leave a comment

Upcoming ASCO abstracts

There are 14 abstracts for the upcoming ASCO that have ALK in the title. But only 6 look like they are likely to be broadly applicable to people on this board. I will be posting summaries over the next week … Continue reading

Posted in 3922 - lorlatinib by Pfizer, alectinib - Alecensa from Chugai - Roche - GenenTech, AP26113 - brigatinib from Ariad, Brain metastases, crizotinib - Xalkori from Pfizer, Lung cancer | Leave a comment

Additional Brigatinib info

Ariad has posted a new presentation from European Lung Cancer Conference on their website for a limited time. Pages 7-13 are most relevant. Page 8 shows a breakdown of how patients  responded by dose. 90 mg had a ORR of … Continue reading

Posted in AP26113 - brigatinib from Ariad, Brain metastases, Lung cancer, Potential Treatments, Research, Side Effects | Leave a comment

Ariad announces start of Phase 3 trial

Ariad today announced the initiation of a first line phase 3 trial comparing Brigatinib with Crizotinib. Patients must be ALK inhibitor naive. They are planning to enroll around 270 patients. They expect to complete enrollment in 2018. Of interest, the … Continue reading

Posted in AP26113 - brigatinib from Ariad, Lung cancer, Potential Treatments, Research | Leave a comment

Brigatinib update

Thanks to Dave for pointing this out. This info can be found on Ariad’s site under Investors, presentations. It’s from the Cowan Healthcare presentation which may only be available for a few weeks. The relevant info is on pages 15-16. … Continue reading

Posted in AP26113 - brigatinib from Ariad, Lung cancer, Potential Treatments, Research | Leave a comment

Article on latest develpments

In January 2016 an article was published that reviewed the current status of nine 2nd generation and 3rd generation ALK inhibitors, some HSP 90 inhibitors and briefly 2 immunotherapies for lung cancer. Much of that research has been described in … Continue reading

Posted in 3922 - lorlatinib by Pfizer, alectinib - Alecensa from Chugai - Roche - GenenTech, AP26113 - brigatinib from Ariad, ASP3026 from Astellas, CEP-37440, ceritinib - Zykadia from Novartis, Imunotherapies, Lung cancer, NMS-E628, Potential Treatments, Research, Resistance to treatment, RXDX-101 - entrectinib - by Ignyta, Side Effects, TSR-011 from Tesaro, X-396 - ensartinib from Xcovrery | Leave a comment